Global Overactive Bladder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Overactive Bladder Treatment Market is presumed to reach the market size of nearly USD 6.54 BN by 2030 from USD 4.33 BN in 2022 with a CAGR of 5.29% under the study period 2023 - 2030.

Overactive bladder (OAB) treatment involves various approaches to managing the symptoms associated with this condition. OAB is characterized by a sudden, involuntary contraction of the muscles in the bladder wall, leading to a frequent and urgent need to urinate. The treatment aims to alleviate symptoms and improve the individual's quality of life.

MARKET DYNAMICS

The Overactive Bladder (OAB) Treatment market is driven by several key factors. A primary contributor is the increasing prevalence of OAB, particularly among the aging population, leading to a rising demand for effective treatment options. Advancements in medical research and pharmaceutical innovation play a crucial role, with the development of targeted medications offering improved efficacy and fewer side effects. The market is further shaped by the growing recognition of behavioral therapies and lifestyle modifications as effective first-line treatments for OAB. This shift towards non-invasive approaches contributes to the expansion of the market for behavioral therapy programs and related interventions. Neuromodulation therapies and surgical interventions for OAB cases resistant to other treatments also influence the market, driven by technological advancements in devices and procedures.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of overactive bladder treatment. The growth and trends of overactive bladder treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the overactive bladder treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Anticholinergics
Mirabegron
Botox
Neuromodulation
Other

By Disease Type

Idiopathic Overactive Bladder
Neurogenic Overactive Bladder

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Overactive Bladder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Overactive Bladder Treatment market include Pfizer, Inc., AbbVie Inc., Astellas Pharma Inc., Medtronic, Sumitomo Pharma America, Inc.( Urovant Sciences.), Viatris Inc., Teva Pharmaceutical Industries Ltd., Hisamitsu Pharmaceutical Co., Inc, Macleods Pharmaceuticals Ltd., Endo International plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112113273

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . OVERACTIVE BLADDER TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Disease Type
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Anticholinergics Historic and Forecast Sales by Regions
5.5 Mirabegron Historic and Forecast Sales by Regions
5.6 Botox Historic and Forecast Sales by Regions
5.7 Neuromodulation Historic and Forecast Sales by Regions
5.8 Other Historic and Forecast Sales by Regions

6 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY DISEASE TYPE

6.1 Overview by Disease Type
6.2 Historical and Forecast Data
6.3 Analysis by Disease Type
6.4 Idiopathic Overactive Bladder Historic and Forecast Sales by Regions
6.5 Neurogenic Overactive Bladder Historic and Forecast Sales by Regions

7 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE OVERACTIVE BLADDER TREATMENT COMPANIES

9.1. Overactive Bladder Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF OVERACTIVE BLADDER TREATMENT INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Pfizer Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. AbbVie Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Astellas Pharma Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Medtronic
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Sumitomo Pharma America Inc.( Urovant Sciences.)
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Viatris Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Teva Pharmaceutical Industries Ltd.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Hisamitsu Pharmaceutical Co. Inc
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Macleods Pharmaceuticals Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Endo International plc
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies